Position of the Transparency Council – Trulicity (dulaglutide)
At its meeting on 8 November 2024, the Transparency Council adopted position No. 122/2024 on the inclusion in reimbursement of the medicinal product Trulicity (dulaglutide) in the indication: Type 2 diabetes mellitus in patients treated with at least two hypoglycemic drugs, with HbA1c ≥ 7.0%, obesity defined as BMI ≥ 30 kg/m2 and very high cardiovascular risk